Key points from article :
Arrive, a startup based in Silicon Valley and Singapore, is leveraging AI to accelerate the development of therapies for age-related diseases. Its deep learning platform integrates ageing cell, tissue, and human data to uncover connections that aid drug discovery. Arrive is unique in the longevity field because it has already gained validation from major pharma companies like Roche, generating revenue by offering its AI platform as a service. The company now aims to expand its mission by raising Series A funding and focusing on in-licensing human-ready compounds while developing novel therapeutics for ageing-related conditions.
Co-founder Andrew Brack, a UCSF professor specializing in cellular biology, teamed up with AI specialist Evan Szu to create the platform. Arrive initially targeted cancer diagnostics to prove its technology, successfully partnering with Roche, which has become a repeat customer. However, the company’s long-term goal is to develop therapies that directly address ageing, combining insights from in-licensed assets with the identification of novel ageing targets.
Arrive’s recent appointment of Anuj Gaggar, a former Gilead executive who played a key role in the development of remdesivir, highlights its commitment to advancing drug development. Gaggar’s extensive connections in biotech and pharma are expected to enhance the company’s strategy for acquiring and developing assets. With a pragmatic focus, Arrive aims to refine its AI capabilities while contributing to the understanding of ageing biology, ultimately improving outcomes for patients with age-related conditions.
